Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Quadrivalent Market From 2025 to 2029?

The size of the quadrivalent market has seen robust growth in the past few years. Its projected growth from $8.87 billion in 2024 to $9.51 billion in 2025, represents a compound annual growth rate (CAGR) of 7.2%. This growth during the historical period can be associated with factors such as complex diseases, educational initiatives, previous health incidents, expansion in healthcare, and technological advancements.

In the coming years, the quadrivalent market is forecasted to experience robust expansion. It is projected to escalate to $13.91 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 10.0%. This projected growth during the forecast period can be ascribed to global health concerns, competitive influences, educational drives, legislative shifts, and changing disease trends. Key trends during the forecast period encompass disease frequency, regulatory conditions, healthcare facilities, public awareness and education, as well as competitive scenarios.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9335&type=smp

What Elements Are Contributing To Growth In The Quadrivalent Market?

The quadrivalent market’s expansion is anticipated to be driven by an increasing incidence of chronic and infectious diseases. Chronic diseases are long-lasting ailments caused by genetics and lifestyle, while infectious diseases result from pathogens such as viruses, bacteria, fungi, or protozoans. Quadrivalent vaccines play a critical role in mitigating the severity and death rate of serious infections, even beyond the specific diseases they are intended to combat. They are employed to prevent chronic (non-communicable) illnesses when infectious agents contribute to cancer development. For instance, data from the Centers for Disease Control and Prevention, a US-based non-profit organization, revealed that in Week 37 of September 2024, 0.5% of specimens were positive for influenza. Of these, 91.4% were influenza A and 8.6% were influenza B. Accumulative data since October 1, 2023 (Week 40), showed that 8.7% of specimens were positive for influenza, with 69.2% being influenza A and 30.8% being influenza B. This depicts a rising overall positivity rate and an increase in the proportion of influenza B cases over time. Consequently, the escalating occurrence of chronic and infectious diseases is steering the growth of the quadrivalent market.

Which Segments Are Detailed In The Global Quadrivalent Market Report?

The quadrivalent market covered in this report is segmented –

1) By Type: Intradermal Shot, Intramuscular Injection, Nasal Spray

2) By Technology: Conjugated, Live, Inactivated, Recombinant, Toxoid, Other Technologies

3) By Disease: Cancer, Hepatitis, Pneumococcal Disease, COVID-19, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus, Other Diseases

4) By Age Group: Pediatric, Adult

5) By Distribution Channel: Hospital And Pharmacy, Government Suppliers, Other Channels (NGOs)

Subsegments:

1) By Intradermal Shot: Standard Intradermal Injection, Needle-Free Intradermal Delivery

2) By Intramuscular Injection: Standard Intramuscular Injection, Adjuvanted Intramuscular Injection

3) By Nasal Spray: Live Attenuated Nasal Spray, Inactivated Nasal Spray

Which Emerging Trends And Strategic Shifts Are Shaping The Quadrivalent Market?

The rising trend of product innovation is gaining traction in the quadrivalent industry. Many substantial companies in this market are turning towards the creation of novel solutions in order to bolster their market standing. An example of this was in September of 2022 when UK-based AstraZeneca, an eminent pharmaceutical firm, introduced FluMist quadrivalent. This FDA-approved influenza vaccination is a needle-free nasal spray suitable for individuals aged from 2 to 49 years old, marking a new development in the quadrivalent market. Available in either trivalent or quadrivalent formulations, FluMist serves as a live attenuated influenza vaccine (LAIV) and is included as part of several health insurance plans and the children’s vaccination program.

Who Are The Key Contributors To Growth In The Quadrivalent Market?

Major companies operating in the quadrivalent market include AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Pfizer Inc., Bio Med Pvt. Ltd., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Emergent BioSolutions Inc., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG)

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/quadrivalent-global-market-report

Which Region Is Projected To Lead The Quadrivalent Market By 2025?

North America was the largest region in the quadrivalent market in 2024. The regions covered in the quadrivalent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9335&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model